Quarterly report pursuant to Section 13 or 15(d)

Fair Value of Financial Instruments - Summary of Reconciliation of Changes for All Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)

v3.22.2.2
Fair Value of Financial Instruments - Summary of Reconciliation of Changes for All Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring - Level 3 significant unobservable inputs - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance $ 2,329,044,000 $ 2,202,362,000
Net Realized Gains (Losses) [1] 7,402,000 (61,480,000)
Net Change in Unrealized Appreciation (Depreciation) [2] (40,376,000) 83,500,000
Purchases [3] 869,250,000 944,004,000
Sales 88,282,000 6,498,000
Repayments [4] 314,417,000 754,373,000
Gross Transfers into Level 3 [5] 207,000  
Gross Transfers out of Level 3 13,868,000 [5] 19,061,000 [6]
Ending Balance 2,748,960,000 2,388,454,000
Senior Secured    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 2,156,709,000 2,079,465,000
Net Realized Gains (Losses) [1] (1,883,000) (3,744,000)
Net Change in Unrealized Appreciation (Depreciation) [2] (11,377,000) 7,066,000
Purchases [3] 854,978,000 884,833,000
Sales 73,500,000  
Repayments [4] 314,417,000 754,373,000
Gross Transfers out of Level 3 [5] 3,504,000  
Ending Balance 2,607,006,000 2,213,247,000
Escrow Receivables    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 561,000 65,000
Net Realized Gains (Losses) [1] 401,000 584,000
Net Change in Unrealized Appreciation (Depreciation) [2] (328) (1,515,000)
Purchases [3] 1,148,000 2,473,000
Sales 500,000 1,036,000
Ending Balance 1,282,000 571,000
Unsecured Debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 52,890,000 14,970,000
Net Change in Unrealized Appreciation (Depreciation) [2] (1,880,000) (1,194,000)
Purchases [3] 3,383,000 36,519,000
Ending Balance 54,393,000 50,295,000
Preferred Note    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 69,439,000 58,981,000
Net Realized Gains (Losses) [1] 7,966,000  
Net Change in Unrealized Appreciation (Depreciation) [2] (22,458,000) 54,508,000
Purchases [3] 3,614,000 13,954,000
Sales 11,101,000 61,732,000
Gross Transfers out of Level 3 6,422,000 [5] 1,267,000 [6]
Ending Balance 41,038,000 64,444,000
Common Stock    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 21,968,000 27,398,000
Net Realized Gains (Losses) [1] (74,000) (60,904,000)
Net Change in Unrealized Appreciation (Depreciation) [2] 9,462,000 15,592,000
Purchases [3]   4,371,000
Sales 19 (60,900,000)
Gross Transfers into Level 3 [5] 207,000  
Gross Transfers out of Level 3 3,942,000 [5] 16,025,000 [6]
Ending Balance 27,602,000 31,332,000
Warrant    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Beginning Balance 27,477,000 21,483,000
Net Realized Gains (Losses) [1] 992,000 2,584,000
Net Change in Unrealized Appreciation (Depreciation) [2] (13,795,000) 9,043,000
Purchases [3] 6,127,000 1,854,000
Sales 3,162,000 4,630,000
Gross Transfers out of Level 3 [6]   1,769,000
Ending Balance $ 17,639,000 $ 28,565,000
[1] Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations.
[2] Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations.
[3] Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds.
[4] Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.
[5] Transfers out of Level 3 during the nine months ended September 30, 2022 related to the initial public offerings of Gelesis, Inc., Pineapple Energy, LLC, and the conversion of Level 3 debt investments into common stock investments. Transfers into Level 3 during the nine months ended September 30, 2022 related to the decline of liquidity of Kaleido Biosciences, Inc. shares.
[6] Transfers out of Level 3 during the nine months ended September 30, 2021, related to the initial public offerings of Proterra, Inc., 23andMe, Inc., Sprinklr, Inc., Century Therapeutics, Couchbase, Inc., and Xometry, Inc. There was no activity related to transfers into Level 3 during the nine months ended September 30, 2021.